Needham downgraded Steris from Buy to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/15/2025 | $276.00 | Equal-Weight → Overweight | Morgan Stanley |
| 5/29/2025 | $263.00 | Hold | Jefferies |
| 10/24/2024 | $230.00 → $260.00 | Neutral → Overweight | Piper Sandler |
| 2/6/2024 | $253.00 | Overweight | KeyBanc Capital Markets |
| 5/30/2023 | $206.00 | Equal-Weight | Morgan Stanley |
| 4/14/2023 | $215.00 → $197.00 | Overweight → Neutral | Piper Sandler |
| 9/23/2022 | Buy → Hold | Needham | |
| 7/14/2022 | $240.00 | Overweight | Piper Sandler |
4 - STERIS plc (0001757898) (Issuer)
3 - STERIS plc (0001757898) (Issuer)
4 - STERIS plc (0001757898) (Issuer)
144 - STERIS plc (0001757898) (Subject)
144 - STERIS plc (0001757898) (Subject)
10-Q - STERIS plc (0001757898) (Filer)
Morgan Stanley upgraded Steris from Equal-Weight to Overweight and set a new price target of $276.00
Jefferies initiated coverage of Steris with a rating of Hold and set a new price target of $263.00
Piper Sandler upgraded Steris from Neutral to Overweight and set a new price target of $260.00 from $230.00 previously
DUBLIN, IRELAND, Jan. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on March 19, 2026, to shareholders of record at the close of business on February 17, 2026. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and serv
DUBLIN, IRELAND, Jan. 21, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2026 third quarter results at 9:00 a.m. ET on February 5, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on February 4, 2026. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on February 5, 2026, either
Mettler-Toledo International Inc. (NYSE:MTD) announced today that Michael J. Tokich has been appointed to its Board of Directors, effective February 5, 2026. Mr. Tokich served for over 17 years as Senior Vice President and Chief Financial Officer ("CFO") at STERIS plc (NYSE:STE), a leading global healthcare and life science provider of products and services, prior to recently transitioning to the role of Senior Financial Advisor at STERIS. Mr. Tokich joined STERIS in 2000 and held various senior financial roles prior to his appointment as CFO in 2008. Roland Diggelmann, Chair of the Board, stated, "Mike is a highly accomplished executive who brings nearly two decades of U.S. public comp
Mettler-Toledo International Inc. (NYSE:MTD) announced today that Michael J. Tokich has been appointed to its Board of Directors, effective February 5, 2026. Mr. Tokich served for over 17 years as Senior Vice President and Chief Financial Officer ("CFO") at STERIS plc (NYSE:STE), a leading global healthcare and life science provider of products and services, prior to recently transitioning to the role of Senior Financial Advisor at STERIS. Mr. Tokich joined STERIS in 2000 and held various senior financial roles prior to his appointment as CFO in 2008. Roland Diggelmann, Chair of the Board, stated, "Mike is a highly accomplished executive who brings nearly two decades of U.S. public comp
SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today that the Company's Board of Directors (the "Board") has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the "Cooperation Agreement") with Browning West, LP. ("Browning West"). Mr. Rosebrough will join the Board's Corporate Governance & Nominating Committee. The Board has also agreed that, by the end of 2026, it shall provide due and serious consideration for Mr. Rosebrough to be appointed Chair of the Board. In
DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal
DUBLIN, IRELAND, Jan. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on March 19, 2026, to shareholders of record at the close of business on February 17, 2026. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and serv
DUBLIN, IRELAND, Jan. 21, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2026 third quarter results at 9:00 a.m. ET on February 5, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on February 4, 2026. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on February 5, 2026, either
Total revenue from continuing operations increased 10%; constant currency organic revenue grew 9%As reported EPS from continuing operations increased to $1.94; adjusted EPS increased to $2.47Fiscal 2026 constant currency organic revenue, EPS and free cash flow outlook increased DUBLIN, IRELAND , Nov. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 second quarter ended September 30, 2025. Total revenue from continuing operations for the second quarter of fiscal 2026 increased 10% to $1.5 billion compared with $1.3 billion in the second quarter of fiscal 2025. Constant currency organic revenue growth from
SC 13G/A - STERIS plc (0001757898) (Subject)
SC 13G/A - STERIS plc (0001757898) (Subject)
SC 13G/A - STERIS plc (0001757898) (Subject)